Publications

Recent publications of the EUTOS 2018 project:

Katerina Machova Polakova, Hana Zizkova, Jan Zuna, Eliska Motlova, Lenka Hovorkova, Andrea Gottschalk, Ingmar Glauche, Jitka Koblihova, Pavla Pecherkova, Hana Klamova, Marketa Stastna Markova, Dana Srbova, Adela Benesova, Vaclava Polivkova, Tomas Jurcek, Daniela Zackova, Jiri Mayer, Thomas Ernst, Francois X. Mahon, Susanne Saussele, Ingo Roeder, Nicholas C. P. Cross & Andreas Hochhaus. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia. 2020. https://doi.org/10.1038/s41375-020-0882-1

Michel, C., Burchert, A., Hochhaus, A., Saussele, S., Neubauer, A., Lauseker, M., et al.. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2019, 104(5), 955–962. http://doi.org/10.3324/haematol.2018.206797

Recent publications of the EUTOS 2016 project:

Cross NCP, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia. 2016;30:1844-52. doi: 10.1038/leu.2016.90 PMID: 27109508

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen J, Ossenkoppele G, Porkka K, Wolf D.: Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor (TKI) therapy in early Chronic Phase Chronic Myelogenous Leukemia (CML-CP). J Clin Oncol. 2017. 35(2):175-184. PMID:28056193

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30. PMID: 29381150

Sopper S, Mustjoki S, Gjertsen BT, et al. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2017 Oct;31(10):2264-2267. DOI: 10.1038/leu.2017.235.

Brück O, Blom S, Dufva O, et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 2018;32(7):1643‐1656. DOI:10.1038/s41375-018-0175-0

Inselmann et al., Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. (2018). Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. Cancer Res.  2018 (78) (21) 6223-6234; http://doi.org/10.1158/0008-5472.CAN-18-1477

Michel C, Burchert A, Hochhaus A, et al. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2019;104(5):955‐962. DOI:10.3324/haematol.2018.206797

Möbius S, Schenk T, Himsel D, et al. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol. 2019;145(6):1645‐1650. DOI:10.1007/s00432-019-02910-6